These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29263774)

  • 1. Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.
    Ayyagari R; Neary M; Li S; Rokito A; Yang H; Xie J; Benson AB
    Am Health Drug Benefits; 2017 Nov; 10(8):408-415. PubMed ID: 29263774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
    Barnes JI; Lin JK; Gupta D; Owens DK; Goldhaber-Fiebert JD; Kunz PL
    J Natl Compr Canc Netw; 2020 Sep; 18(9):1200-1209. PubMed ID: 32886901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
    Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
    Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.
    Ryan P; McBride A; Ray D; Pulgar S; Ramirez RA; Elquza E; Favaro JP; Dranitsaris G
    J Oncol Pharm Pract; 2019 Sep; 25(6):1425-1433. PubMed ID: 30924737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cost-effectiveness analysis of octreotide long acting release and lanreotide slow release for the treatment of postoperative patients with active acromegaly in China].
    Xuan JW; Zhang ZY; Wang YF; Mao ZG; Lu YJ; Wang RZ
    Zhonghua Yi Xue Za Zhi; 2017 Mar; 97(10):765-769. PubMed ID: 28316158
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
    Clarke CN; Cockrum P; Beveridge TJR; Jerry M; McMorrow D; Tran AT; Phan AT
    J Health Econ Outcomes Res; 2023; 10(2):121-131. PubMed ID: 38093906
    [No Abstract]   [Full Text] [Related]  

  • 7. A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors.
    Seo C; Horodniceanu E; Shah R; Goldstein G; Ray D; Bennett B; Phan A; McCarrier K
    Support Care Cancer; 2022 Jul; 30(7):6307-6316. PubMed ID: 35476113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
    Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
    Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
    Ström T; Kozlovacki G; Myrenfors P; Almquist M
    Patient Prefer Adherence; 2019; 13():1799-1807. PubMed ID: 31695341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Saif MW; Fu J; Smith MH; Weinstein B; Relias V; Daly KP
    J Pancreat Cancer; 2018; 4(1):64-71. PubMed ID: 30788459
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].
    Bencsiková B
    Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Lutetium [
    Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
    J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
    Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
    Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lutetium oxodotreotide (
    Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
    BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly.
    Turner HE; Lindsell DR; Vadivale A; Thillainayagam AV; Wass JA
    Eur J Endocrinol; 1999 Dec; 141(6):590-4. PubMed ID: 10601961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
    Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
    Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.